November 15, 2019 New Novartis Medicine Adakveo® (crizanlizumab) Approved by FDA to Reduce Frequency of Pain Crises in Individuals Living with Sickle Cell Disease Therapy developed by MPM portfolio company Selexys, acquired by Novartis in 2016 Read full article